Eli Lilly and its manufacturing partner Resilience are putting $750 million into a Cincinnati-area buildout, all of it going toward one job: churning out more KwikPen injectors for Zepbound and Lilly’s diabetes drugs. No equity changed hands here. This is a capacity deal, not an acquisition, and that distinction tells you what kind of buyer Lilly is right now.
The $750 million investment adds at least 400 jobs and pushes Resilience’s Ohio headcount past 1,400. Full operations start early 2027. What Lilly gets: guaranteed domestic supply of the four-dose KwikPen that won FDA approval in February for Zepbound, already the most prescribed weight-loss drug of 2025. This buys capacity for a product already selling, not a bet on some future pipeline.
This isn’t Lilly’s first check to Resilience, and it won’t be the last. Rather than break ground on a new plant, the Cincinnati deal expands an existing CDMO relationship already in place, the fastest way to add supply.
Resilience is the other side of this trade worth watching. Launched in 2020 with over $800 million from Arch Venture Partners and 8VC, it’s since raised almost $2.5 billion, plus a Department of Defense loan, betting that pharma would rather rent capacity than build it. Lilly’s $750 million check, and 150 million doses already produced, is the proof that bet paid off.
Diana Kowalski